vs
Rapid7, Inc.（RPD）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是再鼎医药的1.7倍（$217.4M vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 3.0%）
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
RPD vs ZLAB — 直观对比
营收规模更大
RPD
是对方的1.7倍
$127.1M
营收增速更快
ZLAB
高出16.6%
0.5%
自由现金流更多
RPD
多$63.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $217.4M | $127.1M |
| 净利润 | $3.1M | — |
| 毛利率 | 68.9% | 51.0% |
| 营业利润率 | 1.0% | -54.6% |
| 净利率 | 1.4% | — |
| 营收同比 | 0.5% | 17.1% |
| 净利润同比 | 44.1% | — |
| 每股收益（稀释后） | $0.05 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RPDZLAB
| Q4 25 | $217.4M | $127.1M | ||
| Q3 25 | $218.0M | $115.4M | ||
| Q2 25 | $214.2M | $109.1M | ||
| Q1 25 | $210.3M | $105.7M | ||
| Q4 24 | $216.3M | $108.5M | ||
| Q3 24 | $214.7M | $101.8M | ||
| Q2 24 | $208.0M | $100.1M | ||
| Q1 24 | $205.1M | $87.1M |
净利润RPDZLAB
| Q4 25 | $3.1M | — | ||
| Q3 25 | $9.8M | $-36.0M | ||
| Q2 25 | $8.3M | $-40.7M | ||
| Q1 25 | $2.1M | $-48.4M | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $15.4M | $-41.7M | ||
| Q2 24 | $6.5M | $-80.3M | ||
| Q1 24 | $1.4M | $-53.5M |
毛利率RPDZLAB
| Q4 25 | 68.9% | 51.0% | ||
| Q3 25 | 70.2% | 59.5% | ||
| Q2 25 | 70.6% | 60.6% | ||
| Q1 25 | 71.7% | 63.6% | ||
| Q4 24 | 69.5% | 61.5% | ||
| Q3 24 | 70.6% | 64.1% | ||
| Q2 24 | 70.7% | 64.9% | ||
| Q1 24 | 70.3% | 61.4% |
营业利润率RPDZLAB
| Q4 25 | 1.0% | -54.6% | ||
| Q3 25 | 2.7% | -42.3% | ||
| Q2 25 | 1.6% | -50.3% | ||
| Q1 25 | -0.0% | -53.3% | ||
| Q4 24 | 3.4% | -62.6% | ||
| Q3 24 | 6.0% | -66.6% | ||
| Q2 24 | 2.5% | -76.0% | ||
| Q1 24 | 4.7% | -80.7% |
净利率RPDZLAB
| Q4 25 | 1.4% | — | ||
| Q3 25 | 4.5% | -31.2% | ||
| Q2 25 | 3.9% | -37.3% | ||
| Q1 25 | 1.0% | -45.8% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 7.2% | -40.9% | ||
| Q2 24 | 3.1% | -80.2% | ||
| Q1 24 | 0.7% | -61.4% |
每股收益（稀释后）RPDZLAB
| Q4 25 | $0.05 | $-0.05 | ||
| Q3 25 | $0.15 | $-0.03 | ||
| Q2 25 | $0.13 | $-0.04 | ||
| Q1 25 | $0.03 | $-0.04 | ||
| Q4 24 | $0.08 | $-0.09 | ||
| Q3 24 | $0.21 | $-0.04 | ||
| Q2 24 | $0.09 | $-0.08 | ||
| Q1 24 | $0.02 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $474.7M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $154.7M | $715.5M |
| 总资产 | $1.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RPDZLAB
| Q4 25 | $474.7M | $689.6M | ||
| Q3 25 | $407.1M | $717.2M | ||
| Q2 25 | $511.7M | $732.2M | ||
| Q1 25 | $493.5M | $757.3M | ||
| Q4 24 | $521.7M | $779.7M | ||
| Q3 24 | $443.7M | $616.1M | ||
| Q2 24 | $442.6M | $630.0M | ||
| Q1 24 | $411.7M | $650.8M |
股东权益RPDZLAB
| Q4 25 | $154.7M | $715.5M | ||
| Q3 25 | $127.2M | $759.9M | ||
| Q2 25 | $90.4M | $791.7M | ||
| Q1 25 | $52.7M | $810.8M | ||
| Q4 24 | $17.7M | $840.9M | ||
| Q3 24 | $-5.1M | $667.7M | ||
| Q2 24 | $-52.6M | $704.2M | ||
| Q1 24 | $-86.4M | $762.2M |
总资产RPDZLAB
| Q4 25 | $1.7B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.6B | $985.3M | ||
| Q2 24 | $1.5B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $36.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 16.8% | -21.0% |
| 资本支出强度资本支出/营收 | 0.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 12.01× | — |
| 过去12个月自由现金流最近4个季度 | $146.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流RPDZLAB
| Q4 25 | $37.6M | $-26.0M | ||
| Q3 25 | $39.0M | $-32.0M | ||
| Q2 25 | $47.5M | $-31.0M | ||
| Q1 25 | $29.8M | $-61.7M | ||
| Q4 24 | $63.8M | $-55.8M | ||
| Q3 24 | $44.0M | $-26.8M | ||
| Q2 24 | $32.9M | $-42.2M | ||
| Q1 24 | $31.1M | $-90.1M |
自由现金流RPDZLAB
| Q4 25 | $36.4M | $-26.7M | ||
| Q3 25 | $34.8M | $-35.0M | ||
| Q2 25 | $46.6M | $-33.9M | ||
| Q1 25 | $28.4M | $-63.2M | ||
| Q4 24 | $62.6M | $-58.4M | ||
| Q3 24 | $42.6M | $-28.2M | ||
| Q2 24 | $32.6M | $-42.9M | ||
| Q1 24 | $30.4M | $-91.1M |
自由现金流率RPDZLAB
| Q4 25 | 16.8% | -21.0% | ||
| Q3 25 | 16.0% | -30.4% | ||
| Q2 25 | 21.8% | -31.1% | ||
| Q1 25 | 13.5% | -59.9% | ||
| Q4 24 | 28.9% | -53.8% | ||
| Q3 24 | 19.9% | -27.7% | ||
| Q2 24 | 15.7% | -42.9% | ||
| Q1 24 | 14.8% | -104.5% |
资本支出强度RPDZLAB
| Q4 25 | 0.5% | 0.5% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 0.4% | 2.6% | ||
| Q1 25 | 0.6% | 1.5% | ||
| Q4 24 | 0.5% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
现金转化率RPDZLAB
| Q4 25 | 12.01× | — | ||
| Q3 25 | 3.97× | — | ||
| Q2 25 | 5.70× | — | ||
| Q1 25 | 14.14× | — | ||
| Q4 24 | 29.36× | — | ||
| Q3 24 | 2.85× | — | ||
| Q2 24 | 5.03× | — | ||
| Q1 24 | 22.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
